April 2011

Q&A: Manufacturing an "extra hurdle" for personalized medicine
Jeff Abbey, CEO of Argos, talked with R&D Directions about the unique challenges associated with manufacturing personalized inmunotherapies, and the potential for new automated technologies to address these hurdles.

Q&A: Open innovation a necessary path for pharma
Dwayne Spradlin, CEO of InnoCentive, an online matchmaker for problem solvers, says large pharmaceutical companies need to adopt strategies in open innovation.

March 2011

Communications breakdown
Patient recruitment experts recount some of the common areas where communications strategies might typically fail.

Ad agencies engage in emerging markets
Healthcare advertising agencies are following their clients’ lead by making investments in emerging markets.

February 2011

The telaprevir edge
Peter Mueller, Ph.D., executive VP, global research and development, and chief scienti? c of? cer, Vertex, discusses what gives telaprevir an edge over other treatment options and the advantages of using the drug in combination with the non- nucleoside polymerase inhibitor VX-222.

A diagnostics marketing primer
Dianah Schmidt, executive director, marketing & services, for the diagnostics company Accumetrics, discusses her company’s marketing and reimbursement strategies.

Q&A: Trial insurance terrain in China uncharted territory

Q&A: Untapped data sources could aid patient recruitment

January 2011

Concentric’s view for ‘11
Ken Begasse Jr, partner, chief operating officer, and Michael Sanzen, partner, chief creative officer, Concentric Pharma Advertising (concentric-rx.com) discuss how marketers have begun setting simplified, more actionable data collection goals, along with other trends for 2011.

Docs get it all with digital promotion
Rob Likoff, co-CEO, Group DCA, outlines how state-of-the-art digital promotion can provide everything the physician needs from a product information standpoint. Group DCA (groupdca.com) is a PDI Company.

Lifestyle influences health in China/India
Lifestyle changes are contributing to hypertension in a younger population of patients in China, while a shift from communicable diseases to non-communicable diseases is under way in India.

A personal connection
Siren Interactive’s transition into a rare disorder-focused agency began with founder Wendy White’s experience as a caregiver for her daughter.

Q&A: Bristol-Myers Squibb R&D head Elliott Sigal
Elliott Sigal, executive VP, chief scientific officer and president, research and development, Bristol-Myers Squibb, talks with R&D Directions about the company’s anticipated late-stage candidates in advanced melanoma and atrial fibrillation and its recent key acquisition in the hepatitis C space.

Q&A: Amgen chief medical officer Sean Harper
Sean Harper, senior VP of global development and corporate chief medical officer, Amgen Inc., speaks with R&D Directions about expectations for the company’s new bone drug, denosumab, a compound coming off its second approval in six months.